⌘K
t
AstraZeneca PLC shareholders, at a General Meeting held on 3 November 2025, approved a special resolution to adopt new articles of association. The resolution passed with 1,222,275,967 votes (99.36% of votes cast) in favour and 7,861,875 votes (0.64% of votes cast) against, representing 79.33% of the total issued share capital voted. Subsequent expected events include the termination of the ADR Programme and delisting from Nasdaq by 2 February 2026, with trading on the NYSE expected to commence by 8:00 a.m. (ET) on the same date.
| Date | 3 Nov 2025 |
| Time | 16:00:00 |
| Category | AGMs and other meetings |
| ID | 9795F |
3 November 2025
AstraZeneca PLC (the 'Company') announced that at the General Meeting ('GM') of shareholders held earlier today, shareholders approved the resolution to adopt new articles of association of the Company, as required to proceed with the harmonisation of the Company's equity listing structure. As proposed in the Circular and Notice of GM circulated on 29 September 2025, the Resolution was decided by poll vote and was passed as a special resolution.
|
|
Votes for |
% of votes cast |
Votes against |
% of votes cast |
Votes cast in total |
Total votes cast as a % of issued share capital |
Votes withheld |
|
To adopt new articles of association of the Company in connection with the harmonisation of its equity listing structure |
1,222,275,967 |
99.36 |
7,861,875 |
0.64 |
1,230,137,842 |
79.33 |
2,628,613 |
Michel Demaré, Chair AstraZeneca said: "Today's significant vote in favour of the Board's proposal demonstrates strong shareholder support for AstraZeneca's harmonised listing structure in London, Stockholm and New York. As the Company continues to expand and invest in our growing markets, our new structure will offer the flexibility to access the broadest available pool of capital, including in the US, enabling more shareholders to participate in AstraZeneca's exciting future."
The expected timetable of principal events as set out in the Circular and Notice of GM remains unchanged and is replicated below. The following dates and times are indicative only and are subject to change. If any of the dates set out in the timetable change, the Company will give notice of this change by issuing an announcement through a Regulatory News Service.
|
Expected date for termination of ADR Programme, delisting of AstraZeneca ADSs and cancellation of the listing and trading of AstraZeneca US Bonds on Nasdaq |
2 February 2026
|
|
Expected time and date for commencement of trading in AstraZeneca Shares and AstraZeneca US Bonds on the NYSE |
By 8:00 a.m. (ET) on 2 February 2026 |
|
Expected date for the issuance of AstraZeneca DIs to relevant CREST participant accounts |
On or around 2 February 2026 |
|
Expected date for the issuance of statements of entitlement for existing CSN Eligible Certificated Shareholders and CSN Participants |
By no later than 16 February 2026 |
A copy of the special resolution passed at the GM has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
As at 30 October 2025, the number of issued shares of the Company was 1,550,712,906 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against the Resolution. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca.
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC